Inhibition of mammalian carbonic anhydrases I-XIV with grayanotoxin III: Solution and in silico studies

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 4, 2014, Pages 469-475

  Durdagi, Serdar ^a,b   Scozzafava, Gabriele ^c   Vullo, Daniela ^c   Sahin, Hüseyin ^d   Kolayli, Sevgi ^d   Supuran, Claudiu T ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b BAHCESEHIR UNIVERSITY   (Turkey)

^c UNIVERSITY OF FLORENCE   (Italy)

^d KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Carbonic anhydrase; Grayanotoxin III; Molecular docking

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE III; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE V; CARBONATE DEHYDRATASE VI; CARBONATE DEHYDRATASE VII; CARBONATE DEHYDRATASE VIII; CARBONATE DEHYDRATASE X; CARBONATE DEHYDRATASE XI; CARBONATE DEHYDRATASE XII; CARBONATE DEHYDRATASE XIII; CARBONATE DEHYDRATASE XIV; DICLOFENAMIDE; GRAYANOTOXIN; GRAYANOTOXIN III; SULFONAMIDE; UNCLASSIFIED DRUG; DITERPENE; ISOENZYME; SOLUTION AND SOLUBILITY;

ARTICLE; COMPUTER MODEL; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DOSE RESPONSE; METABOLISM; SOLUTION AND SOLUBILITY; STRUCTURE ACTIVITY RELATION;

CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; COMPUTER SIMULATION; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904337326     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.804072     Document Type: Article

References (45)

1. Chen SN, Zhang HP, Wang LQ, et al. Diterpenoids from the flowers of Rhododendron molle. J Nat Prod 2004;67:1903-6.
2. Terai T, Sato M, Narama I, et al. Transformation of grayanotoxin III to 10-epi-grayanotoxin III. Its X-ray crystallographic analysis and acute toxicity in mice. Chem Pharm Bull (Tokyo) 1996;44: 1245-7.
3. Koca I, Koca AF. Poisoning by mad honey: A brief review. Food Chem Toxicol 2007;45:1315-18.
4. Burke JW, Doskotch RW. High field 1H- And 13C-nmr assignments of grayanotoxins I, IV, and XIV isolated from Kalmia angustifolia. J Nat Prod 1990;53:131-7.
5. Akera T, Ku DD, Frank M, et al. Effects of grayanotoxin I on cardiac Na - K - -Adenosine triphosphatase activity, transmembrane potential and myocardial contractile force. J Pharmacol Exp Ther 1976;199:247-54.
6. Sahin H, Aliyazicioglu R, Yildiz O, et al. Honey, pollen, and propolis extracts show potent inhibitory activity against the zinc metalloenzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2011;26:440-4.
7. Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7: 168-81.
8. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74.
9. Supuran CT. Bacterial carbonic anhydrases as drug targets: Toward novel antibioticŞ. Front. Pharmacol 2011;2:1-6.
10. Pastorekova S, Parkkila S, Pastorek J, et al. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199-229.
11. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Reviews Drug Discovery 2011;10: 767-77.
12. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89.
13. Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-Associated carbonic anhydrase IX to acidify extracellular pH. Febs Lett 2004;577:439-45.
14. Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem 2009;24:1-39.
15. Wykoff CC, Beasley NJ, Watson PH. Hypoxia-inducible expression of tumor-Associated carbonic anhydrases. Cancer Res 2000;60: 7075-83.
16. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
17. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896-902.
18. Supuran CT. Diuretics: From classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Design 2008; 14:641-8.
19. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugŞ. Curr Pharm Design 2008;14:655-60.
20. Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: Coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-62.
21. Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511-22.
22. Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors: Interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg Med Chem Lett 2008;18: 1583-7.
23. Davis RA, Hofmann A, Osman A, et al. Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases. J Med Chem 2011;54:1682-92.
24. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. The Journal of Biological Chemistry 1971; 246:2561-73.
25. Alterio V, Di Fiore A, D'Ambrosio K, et al. X-ray crystallography of CA inhibitors and its importance in drug design. In: Supuran CT, Winum JY, eds. Drug design of zinc-enzyme inhibitors: Functional, structural, and disease applications. Hoboken (NJ): Wiley; 2009:73-138.
26. Alterio V, Di Fiore A, D'Ambrosio K, et al. Crystal structure of the catalytic domain of the tumor-Associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A 2009;106:16233-8.
27. Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841-5.
28. Avvaru BS, Wagner JM, Maresca A, et al. Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. Bioorg Med Chem Lett 2010;20:4376-81.
29. Wagner J, Avvaru BS, Robbins AH, et al. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: Solution and crystallographic investigations. Bioorg Med Chem 2010;18:4873-8.
30. Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun 2010;46: 8371-3.
31. Temperini C, Innocenti A, Scozzafava A, et al. The coumarinbinding site in carbonic anhydrase accommodates structurally diverse inhibitors: The antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010;53:850-4.
32. Durdagi S, Senturk M, Ekinci D, et al. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII: Evidence of a new binding mode within the enzyme active site. Bioorg Med Chem 2011;19:1381-9.
33. Balaydin H, Turker H, Durdagi S, et al. Inhibition of human carbonic anhydrase isozymes I, II, and VI with a series of bisphenol, methoxy and bromophenol compounds. J Enzy Inh Med Chem 2012;27:467-75.
34. Innocenti A, Durdagi S, Doostdar N, et al. Nanoscale enzyme inhibitors: Fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorg Med Chem 2010;18: 2822-8.
35. Talaz O, Cavdar H, Durdagi S, et al. Synthesis of 1,4-bis(indolin-1- ylmethyl)benzene derivatives and their structure-Activity relationships for the interaction of human carbonic anhydrase isoforms I and II. Bioorg Med Chem 2013;21:1477-82.
36. Friesner RA, Murphy RB, Repasky Frye LL, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49: 6177-96.
37. Subbotina J, Yarov-Yarovoy V, Lees-Miller J, et al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane de-novo modeling and molecular-dynamics simulations. Proteins: Struct Funct Bioinform 2010;78:2922-34.
38. Cakmak R, Durdagi S, Ekinci D, et al. Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors. Bioorg Med Chem Lett 2011;21:5398-402.
39. Politi A, Durdagi S, Moutevelis-Minakakis P, et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mol Graph Model 2010; 29:425-35.
40. Durdagi S, Zhao C, Cuervo JE, Noskov SY. Atomistic models for free energy evaluation of drug binding to membrane proteins. Curr Med Chem 2011;18:2601-11.
41. Mavromoustakos T, Durdagi S, Koukoulitsa C, et al. Strategies in the rational drug design. Curr Med Chem 2011;18:2517-30.
42. Durdagi S, Subbotina J, Lees-Miller J, et al. Insights into molecular mechanism of herg1 channel activation and blockade by drugs. Curr Med Chem 17: 3514-32.
43. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activators: The first X-ray crystallographic study of an adduct of isoform I. Bioorg Med Chem Lett 2006;16:5152-56.
44. Milne RI, Abbott RJ. Origin and evolution of invasive naturalized material of Rhododendron ponticum L. in the British Isles. Mol Ecol 2000;9:541-56.
45. Food and Agriculture Organization of the United Nations. Data available at: Http://faostat.fao.org/site/339/default.aspx [last accessed 22 Jul 2013].